Nexalin Technology (NXL) CEO Mark White: FDA Trials, At-Home Neurostimulation, and 2026 Milestones

In our investor-focused interview, Mark White, CEO of Nexalin Technology (Nasdaq: NXL), breaks down how the company is building a non-invasive neurostimulation platform aimed at major unmet needs across brain health, including depression, insomnia, PTSD/TBI, and Alzheimer’s/dementia.Nexalin’s mission is to lead what it calls the “brain health movement” with treatment designed to be safe, effective, and drug-free, supported by a growing body of peer-reviewed research and a roadmap centered on Mood, Military, and Memory.Nexalin’s edge is its frequency-based approach designed to emulate natural brain activity through Deep Intracranial Frequency Stimulation (DIFS™). Clinical validation includes peer-reviewed results published in Radiology showing improved cognition and stronger brain network connectivity in mild Alzheimer’s disease. Additional peer-reviewed findings point to broader potential, including blood pressure reduction in depression (Journal of Affective Disorders) and improved attention with normalized brain activity in ADHD (Molecular Psychiatry).👉 Nexalin Technology is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: https://www.NXLinfo.com#NXL #Nexalin #Nasdaq #SmallCapStocks #MicroCapStocks #StockMarket #GrowthStocks #BiotechStocks #MedTech #DigitalHealth #MedicalDevices #Neurostimulation